SANN.SW CHMP opinion: Thursday, July 23, 2026

Variation type II · AGAMREE · Submission of updated comprehensive safety data from studies VBP15‑006, SNT‑I‑VAM‑024, SNT‑I‑VAM‑025, and SNT‑I‑VAM‑026, expanded-access programs, compassionate use and named patient programs as well as data from ongoing clinical trial SNT-IV-VAM-011 and post-marketing

Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.